Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2007-06-05
2007-06-05
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S001690, C514S002600
Reexamination Certificate
active
10341577
ABSTRACT:
New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N-O-P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
REFERENCES:
patent: 4885363 (1989-12-01), Tweedle
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5068222 (1991-11-01), Camble et al.
patent: 5217955 (1993-06-01), Bogden et al.
patent: 5219556 (1993-06-01), Wolfangel
patent: 5244883 (1993-09-01), Cai et al.
patent: 5369094 (1994-11-01), Schally et al.
patent: 5393512 (1995-02-01), Vanderheyden et al.
patent: 5410018 (1995-04-01), Spindel et al.
patent: 5428018 (1995-06-01), Edwards et al.
patent: 5428019 (1995-06-01), Edwards et al.
patent: 5534497 (1996-07-01), Verbruggen
patent: 5620955 (1997-04-01), Knight et al.
patent: 5620959 (1997-04-01), Leban et al.
patent: 5649537 (1997-07-01), Anelli et al.
patent: 5686410 (1997-11-01), Albert et al.
patent: 5834433 (1998-11-01), Krstenansky
patent: 5965695 (1999-10-01), Simon et al.
patent: 6075121 (2000-06-01), Simon et al.
patent: 6200546 (2001-03-01), Hoffman et al.
patent: 6461588 (2002-10-01), Anelli et al.
patent: 6803030 (2004-10-01), De Haen et al.
patent: 2002/0054855 (2002-05-01), Hoffman et al.
patent: 2003/0224998 (2003-12-01), Reubi et al.
patent: 2004/0253225 (2004-12-01), Cappelleti et al.
patent: WO91/01144 (1991-02-01), None
patent: WO96/03427 (1996-02-01), None
Giblin et al. (1998), Proc. Natl. Aca. Sci., USA, vol. 95, pp. 12814-12818.
Walsh et al., Western Journal of Medicine, vol. 155, pp. 152-163, 1991.
Heppeler et al., Receptor Targeting for Tumor Localization and Therapy with Radiopeptides. Current Medicinal Chemistry 2000, 7:971-994.
Sethi et al., Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo, Cancer Res. May 1, 1992;52(9 Suppl):2737s-2742s.
Halmos, T., Wittliff, J.L., and Schally, A.V., Characterization of bombesin/gastrin releasing peptide receptors on human breast cancer and their Relationship to steroid receptor expression, Cancer Research 55:280-287, 1995.
Kelly, K., Kane, M.A., and Bunn, P.A., “Growth factors in lung cancer: Possible etiologic role and clinical target”, Medical and Pediatric Oncology 19:449-458, 1991.
Reile, H., Armatis, P.E., and Schally, A.V., Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells, Prostate, Jul. 1994;25(1):29-38.
Schutte, J., and Seeber, S., “Bombesin antagonists: Experimental and clinical results”, Recent Results in Cancer Research 129:115-129, 1993.
Walsh, J.H., Karnes, W.E., Cuttitta, F., and Walker, A., “Autocrine growth factors and solid tumor malignancy”, Western Journal of Medicine 155: 152-163, 1991.
Leban, et al., Potent gastrin-releasing peptide (GRP) antagonsits derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues, J Med Chem. Feb. 18, 1994;37(4):439-45.
Li, et al.; In-Vivo and In-Vitro Characterization of a Rh-105-Tetrathiamacrocycle Conjugate of a Bombesin Analogue, Proceedings of the 43rd Annual Meeting, vol. 37, No. 5, May 1996 Supplement, p. 61.
Zhu, et al.; Binding, internalization, and processing of bombesin by rat pancreatic acini, Bombesin Binding and Internalization, 1991, pp. G57-G64.
Moody, et al.; BW1023U90: A new GRP Receptor Antagonist for Small-Cell Lung Cancer Cells, Peptides vol. 17, No. 8, pp. 1337-1343, 1996.
Moody, et al.; A GRP Receptor Antagonist Which Inhibits Small-Cell Lung Cancer Growth; Life Sciences, vol. 56, No. 7, pp. 521-529, 1995.
Seifert, et al.; No Carrier Added Preparations of ‘3+1’ Mixed-ligand 99mTc Complexes, Appl. Radiat. Isot. vol. 49, Nos. 1-2, pp. 5-11, 1998.
Smith, et al.; In Vivo and In Vitro Characterization of Novel Water-Soluble Dithio-Bisphosphine 99mTc Complexes, Nuclear Medicine & Biology, vol. 24, pp. 685-691, 1977.
Coy et al, “Short Chain Pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic Acinar and swiss 3T3 cells display strong Antimitotic activity” J. Biol. Chem., vol. 264, No. 25, pp. 14691-14697, 1989.
Thomas et al., Antitumoral Activity of Bombesin Analogues on Small Cell Lung Cancer Xenografts: Relationship with Bombesin Receptor Expression, Cancer Res. Sep. 15, 1992;52(18):4872-7.
Radulovic et al., Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice, Acta Oncol. 1994;33(6):693-701
Qin, et al., Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro, Cancer Res. Feb. 15, 1994;54(4):1035-41.
Qin, et al., Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP, Int J Cancer. Oct. 9, 1995;63(2):257-62.
Cai et al., Potent Bombesin antagonists with C-Terminal Leu-(CH2-N)-Tac-NH2 or its Derivatives, (1994) Proc. Natl. Acad. Sci., 91:12664-12668.
Radulovic, et al., Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi, Int J Pept Protein Res. Dec. 1991;38(6):593-600.
Staley, et al., [Des-Met14]bombesin analogues function as small cell lung cancer bombesin receptor antagonists, Peptides. Jan.-Feb. 1991;12(1):145-9.
Wang et al., Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells, Biochemistry. Jan. 23, 1990;29(3):616-22.
Wang, Knezetic, Schally, Pour, Adrian; Bombesin May Stimulate Proliferation of Human Pancreatic Cancer Cells Through An Autocrine Pathway, Int. J. Cancer: 68, 528-534 (1996).
Yano, Pinski, Groot, Schally, Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines, Cancer Res. Aug. 15, 1992;52(16):4545-7.
Kane, Auguayo, Portanova, Ross, Holley, Kelly, Miller, Isolation of the bombesin/gastrin-releasing peptide receptor from human small cell lung carcinoma NCI-H345 cells, J Biol Chem. May 25, 1991;266(15):9486-93.
Schuller, Receptor-mediated mitogenic signals and lung cancer, Caner Cells. Dec. 1991;3(12):496-503.
Halmos et al., Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression, Cancer Res. Jan. 15, 1995;55(2):280-7.
Hajri et al., Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma, Cancer Res. Jul. 1, 1992;52(13):3726-32.
Fritzberg, et al., Radiolabeling of Antibodies for Targeted Diagnostics, Handbook of Targeted Delivery of Imaging Agents (ed) V.P. Torchilin, CRC Press, Boca Raton, Florida, Chapter 6, pp. 83-101, 1995.
Radulovic, et al., The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers, 1992.
John E. Taylor, Identification and Characterization Somatostatin (SRIF), Gastrin Releasing Peptide (GRP), and Neuromedin B (NMB) Receptors on Established Tumors and Tumor Cell Lines, 1993.
Benya, et al., Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization, and growth: possible role for cyclic AMP, Mol Pharmacol. Aug. 1994;46(2):235-45.
Yano, et al., Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer
Cappelletti Enrico
Lattuada Luciano
Linder Karen E.
Marinelli Edmund R.
Nanjappan Palaniappa
Bracco Imaging, S. p. A.
Jones Dameron L.
Kramer Levin Naftali & Frankel LLP
LandOfFree
Gastrin releasing peptide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastrin releasing peptide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastrin releasing peptide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3838614